title: Percutaneous mitral valve repair with the MitraClip: early results from the MitraClip Asia-Pacific Registry (MARS).
abstract: OBJECTIVE
  Percutaneous MitraClip therapy has been shown to be safe and efficacious in mitral regurgitation (MR). Our aim was to describe early outcomes in patients from the Asia- Pacific region.
  
  
  RESULTS
  The MitraClip Asia-Pacific Registry (MARS) includes data from eight different centres in five countries in the Asia-Pacific region. The primary efficacy outcome was reduction in MR to ≤2+ at 30 days. The safety outcome was 30-day freedom from major adverse events (MAE), defined as the composite of death, myocardial infarction, non-elective cardiac surgery, renal failure, transfusion of ≥2 units of blood, ventilation for >48 hours, septicaemia, and new onset atrial fibrillation. A total of 142 patients underwent the MitraClip procedure from February 2011 to October 2013. Fifty-three point five percent (76) of patients had functional MR, 45.8% (65) had degenerative MR and 0.7% (1) had mixed MR. The acute procedural success rate was 93.7% (133). Thirty-one point seven percent of the patients were in NYHA Class I-II at baseline, compared to 82.1% at 30 days (p<0.001). Zero percent (0) of the patients had ≤2+ MR at baseline compared to 76.8% (109) at 30 days (p<0.001).
  
  
  CONCLUSIONS
  Results from the Asia-Pacific region show that the MitraClip procedure is effective in reducing mitral regurgitation and has favourable short-term safety outcomes.
authors.affiliation: Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.
authors.forename: Khung Keong
authors.initials: KK
authors.lastname: Yeo
authors.forename: Jonathan
authors.initials: J
authors.lastname: Yap
authors.forename: Eric
authors.initials: E
authors.lastname: Yamen
authors.forename: Nasir
authors.initials: N
authors.lastname: Muda
authors.forename: Edgar
authors.initials: E
authors.lastname: Tay
authors.forename: Darren L
authors.initials: DL
authors.lastname: Walters
authors.forename: Teguh
authors.initials: T
authors.lastname: Santoso
authors.forename: Xianbao
authors.initials: X
authors.lastname: Liu
authors.forename: Paul
authors.initials: P
authors.lastname: Jansz
authors.forename: James
authors.initials: J
authors.lastname: Yip
authors.forename: Robaayah
authors.initials: R
authors.lastname: Zambahari
authors.forename: Jurgen
authors.initials: J
authors.lastname: Passage
authors.forename: Tian Hai
authors.initials: TH
authors.lastname: Koh
authors.forename: Jian'an
authors.initials: J
authors.lastname: Wang
authors.forename: Gregory
authors.initials: G
authors.lastname: Scalia
authors.forename: Ivandito
authors.initials: I
authors.lastname: Kuntjoro
authors.forename: Amiliana M
authors.initials: AM
authors.lastname: Soesanto
authors.forename: David
authors.initials: D
authors.lastname: Muller
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001208:Asia; D001315:Australia; D057510:Endovascular Procedures / Q000295:instrumentation* / Q000706:statistics & numerical data; D005260:Female; D019918:Heart Valve Prosthesis Implantation / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000601:surgery*; D012042:Registries; D012189:Retrospective Studies; D016896:Treatment Outcome